Leire Escudero‐Ibarz
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Occupational and environmental lung diseases, Ubiquitin and proteasome pathways
Most-Cited Works
- → Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma(2015)206 cited
- → KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype(2014)176 cited
- → Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4‐34 usage in mucosa‐associated lymphoid tissue lymphoma(2017)32 cited
- → Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing(2015)28 cited
- → Sensitization of the UPR by loss of PPP1R15A promotes fibrosis and senescence in IPF(2021)26 cited
- → Significant functional difference between TNFAIP3 truncation and missense mutants(2016)10 cited
- → Enhancing throughput and robustness of the fibroblast to myofibroblast transition assay(2025)4 cited
- → Erratum: Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma(2016)2 cited
- → DOP132 An integrated single-cell atlas enables the discovery and validation of a novel candidate therapeutic target for Inflammatory Bowel Disease(2025)1 cited
- → Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice(2023)1 cited